Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Debiopharm Stories

2013-09-18 04:23:00

LAUSANNE, Switzerland, September 18, 2013 /PRNewswire/ -- Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer and Unilabs, a leading supplier of clinical laboratory and medical diagnostic imaging services in Europe, signed a collaboration agreement to commercialize Colox(R), a minimally invasive colorectal cancer assay within the Unilabs network. The test will be available initially in the Swiss and Swedish markets. The agreement combines...

2013-09-09 12:27:12

LAUSANNE, Switzerland and KOLKATA, India, September 9, 2013 /PRNewswire/ -- Debiopharm Group (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced the signature of an exclusive...

2013-09-05 04:21:33

LAUSANNE, Switzerland and SAN FRANCISCO, September 5, 2013 /PRNewswire/ -- Go To Market Consulting Inc. (Go To Market), a San Francisco headquartered business development representation and marketing services life sciences consulting firm, and Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, have entered into an alliance to identify and scout West Coast...

2013-09-02 04:21:38

LAUSANNE, Switzerland, September 2, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors. The aim of the study is to identify the dose limiting...

2013-08-29 04:21:12

LAUSANNE, Switzerland, August 29, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs targeting unmet medical needs as well as companion diagnostics, presents today the 'Debiopharm Group(TM)Life Sciences Award 2013' to Professor Gregoire Courtine for his outstanding research on 'Restoring Motor Functions after Spinal Cord Injury'. The two 'Junior Debiopharm Group(TM) Life...

2013-07-04 04:21:49

LAUSANNE, Switzerland, July 4, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery. Under the research framework, Quartz Bio will apply its...

2013-06-24 08:27:52

LAUSANNE, Switzerland and CAMBRIDGE, England, June 24, 2013 /PRNewswire/ -- Alacrita [http://www.alacritaconsulting.com ], the transatlantic life sciences consulting firm, and Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company, have established an alliance to identify oncological, autoimmune, infectious diseases as well as metabolic in-licensing opportunities stemming from the Massachusetts life science cluster. Alacrita will strengthen...

2013-06-19 04:21:31

LAUSANNE, Switzerland and BANGALORE, India, June 19, 2013 /PRNewswire/ -- Aurigene Discovery Technologies, a Bangalore-based biotech focusing on small molecule and peptide drug discovery and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the successful nomination of a development candidate, Debio 0617B. Debio 0617B is a novel...

2013-06-07 04:20:48

LAUSANNE, Switzerland, June 7, 2013 /PRNewswire/ -- Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group(TM), with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by...

2013-06-04 04:21:03

LAUSANNE, Switzerland, June 4, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer (NSCLC), platinum-refractory...